Qian Li
Sun Yat-sen University
20 Papers
44 Citations
Qian Li is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 10, co-authored 20 publications. Previous affiliations of Qian Li include Memorial Hospital of South Bend.
Chat about Author
Papers
LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
Qianfeng Shi,Yudong Li,Shunying Li,Liang Jin,Hongna Lai,Yanqing Wu,Zijie Cai,Mengdi Zhu,Qian Li,Ying Li,Jingru Wang,Yujie Liu,Zongqi Wu,Erwei Song,Qiang Liu +14 more
TL;DR: It is suggested DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer.
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Yinghua Zhu,Yujie Liu,Chao Zhang,Junjun Chu,Yanqing Wu,Yudong Li,Jieqiong Liu,Qian Li,Shunying Li,Qianfeng Shi,Liang Jin,Jianli Zhao,Dong Yin,Sol Efroni,Fengxi Su,Herui Yao,Erwei Song,Qiang Liu +17 more
TL;DR: It is reported that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy including cisplatin and adriamycin, but not to paclitaxel.
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu,Qiang Liu,Ying Li,Qian Li,Fengxi Su,Herui Yao,Shicheng Su,Quanren Wang,Liang Jin,Ying Wang,Wan Yee Lau,Zefei Jiang,Erwei Song +12 more
TL;DR: Camrelizumab combined with apatinib demonstrated favorable therapeutic effects and a manageable safety profile in patients with advanced TNBC and the ORR was dramatically higher than previously reported ORR by anti-PD-1/PD-L1 antibody or apatinIB monotherapy.
141
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Qian Li,Yifan Wang,Weijuan Jia,Heran Deng,Guangdi Li,Weiye Deng,Jiewen Chen,Betty Y.S. Kim,Wen Jiang,Qiang Liu,Jieqiong Liu +10 more
TL;DR: Together, these results demonstrate a dose-dependent synergism between anti-angiogenic therapy and immune checkpoint blockade, thus providing important insights into the optimal strategies for combining immunotherapy with molecular-targeted agents.
Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.
Shunying Li,Hongna Lai,Jieqiong Liu,Yujie Liu,Liang Jin,Yudong Li,Fengtao Liu,Yuhua Gong,Yanfang Guan,Xin Yi,Qianfeng Shi,Zijie Cai,Qian Li,Ying Li,Mengdi Zhu,Jingru Wang,Yaping Yang,Wei Wei,Dong Yin,Erwei Song,Qiang Liu +20 more
- 27 Mar 2020
TL;DR: It is demonstrated that ctDNA can be used to predict tumor response to NAC and prognosis in early breast cancer, providing information to tailor an individual’s therapeutic regimen.
53